Publication for AURKA and PTTG1

Species	Symbol	Function*	Entrez Gene ID*	Other ID	Gene coexpression	CoexViewer
hsa	AURKA	aurora kinase A	6790			[link]
hsa	PTTG1	PTTG1 regulator of sister chromatid separation, securin	9232

Pubmed ID	Priority	Text
29051608	0.98	AURKA, BORA, CCNB1, CCNB2, CDC25C, CDK1, CKS2, CKS1B, PLK1, TOP2A) and mitotic roles of Polo-like kinase (CCNB1, CCNB2, CDC20, CDC25C, KIF23, PLK1, PRC1, PTTG1, RAD1).
	0.96	AURKA, AURKB, BUB1, BUB1B, PLK1, TTK, NEK2, INCENP) and genes involved in spindle assembly, chromosome segregation, as well as cytokinesis (CDC20, HAUS4, KIF22, KNTC1, ANLN, PTTG1, FAM83D, KIF2C, NUMA1, KLHL21, KIF11, CKAP5, TPX2, NUF2, CENPF, NDC80, PBK, REEP4, ARL8A, MIS18BP1, SNX33, etc.).
21589936	0.98	Aurora-A by forming a complex with Aurora-A. PUM2 might control the destruction of Aurora-A through a similar mechanism in regulating the degradation of securin, although it remains to be determined whether APC/CCdh1 is in the PUM2-Aurora-A complex in early mitosis.
28761362	0.97	securin, separase, aurora A, and aurora B, were reduced after TPX2 depletion in prostate cancer cells (Figure 6C).
	0.96	securin, separase, cyclin B1, B2, aurora A, and aurora B proteins in TPX2-targeted cells.
	0.95	securin, separase, and aurora A protein; by contrast, p21 mRNA and protein were upregulated.
32153633	0.97	AURKA, BUB1B, UBE2C, TPX2, RRM2, KIF11, NCAPG, MELK, NUSAP1, MCM4, RFC4, PTTG1, CHEK1, CEP55, DTL) were selected by integrated analysis.
	0.94	AURKA, BUB1B, UBE2C, TPX2, RRM2, KIF11, NCAPG, MELK, NUSAP1, MCM4, RFC4, PTTG1, CHEK1, CEP55, and DTL.
19836940	0.97	Aurora A inactivation by dephosphorylating the kinase directly and also by stabilising PTTG1 (pituitary tumor transforming gene 1), a mammalian securin protein that inhibits Aurora A in vivo and in vitro.
20094045	0.96	AURKA BUB1 BUB3 BUBR1 CDC20 CDK1 cyclin A cyclin B1 KIF11 MAD1 MAD2 MPS1 NEK2 p53 RANBP2 SCC1 securin separase UBCH10
29606879	0.95	securin, seprase, Aurora A, and Aurora B as well as the upregulation of the cell cycle arrest gene p21.
	0.94	securin, seprase, Aurora A, and Aurora B as well as the upregulation of the cell cycle arrest gene p21.
	0.94	securin, separase, cyclin B1, cyclin B2, Aurora A, Aurora B, TPX2, and NDC80 in DTL-targeted cells.
30316293	0.95	PTTG1, AURKA, DDTI4 and CDC20 were downregulated and FEN1, EZH2 and BRCA1 upregulated upon either etoposide or gemcitabine treatment.
	0.94	AURKA, RECQL4, CHEK1, EZH2, HMMR, HSP90AB1, MMP2, E2F1, CKS2, PTTG1, APAF1, RAS, NCL, MCTS1, FEN1, and HIF1A.
24100295	0.94	Securin, CDC20, and AURKA reached a low, almost undetectable, basal level at earlier time points in MAD2L2-deficient cells than controls (Fig. 2, B-E; Table 1).
	0.78	Securin, CDC20, and AURKA, which is an obligate APC/CCDH1 substrate.
28638452	0.94	securin, separase, cyclin B1, B2, Aurora A and Aurora B protein expression in TPX2-targeted cells.
	0.83	securin, separase, cyclin B1, B2, Aurora A and Aurora B proteins in TPX2-targeted cells.
14734534	0.94	securin-CFP (A; securin Delta61-68) or Aurora A-YFP and CFP-Plk1 (B), and fluorescence in mitotic cells was recorded by time-lapse imaging.
24004664	0.93	securin, Aurora A and Cdc6.
32256749	0.93	aurora kinase (AURKA), cell division cycle (CDC20), DNA topoisomerase IIalpha (TOP2A), CCNB2, kinesin family member (KIFC1), protein regulator of cytokinesis (PRC1), KIF20A, Rac GTPase-activating protein 1 (RACGAP1), PTTG1, ubiquitin-conjugating enzyme (UBE2C), maternal embryonic leucine zipper kinase (MELK), NUSAP1, cytoskeleton-associated protein 2 like (CKAP2L) and TK1.
26387737	0.92	Aurora A, Securin, Aurora B and Nek2A, but not c-Myc and Cyclin E, whose expression are not regulated by Parkin (Figure 2D).
	0.90	Aurora A and Aurora B, Cyclin A and Cyclin B, Survivin, Nek2A, and Securin through two adaptor proteins or coactivators, Cdc20 and Cdh1.
	0.54	Aurora A, Aurora B, Cyclin B1, and Securin are highly expressed in many types of tumors.
20003272	0.92	AURKA, and CYCE), as well in the SAC and mitosis (BRCA1, PTTG1, CDC20, BUBR1, MAD2, CENPA, and CENPF) after pRb acute loss in both HCT116wt (HCT) and p53-knockout (HCTp53KO) cells.
21858218	0.92	securin function, PTTG1 regulates G2/M phase transition by inhibiting separase cleavage and aurora kinase A activity.
18025303	0.91	securin, cyclin B1, and aurora A antibodies.
	0.78	Aurora A, securin, and cyclin B1, proteins normally degraded on mitotic exit, were largely absent after 2 h of roscovitine treatment but were retained in cells exposed to the combination of roscovitine and MG132 (Fig. 1 C).
23775192	0.91	securin-Venus (panel 3), Cdc6-Venus (panel 4), and Aurora A-ECFP (panel 5) were imaged by differential interference contrast (DIC, bottom) and fluorescence (top) microscopy.
25088202	0.91	Aurora-A, Aurora-B, Cyclin B1, Cdh1, securin and Plk1 in unsynchronized tamoxifen inducible Wee1 knockout MEFs.
30720105	0.91	AURKA, aurora kinase A; CDC20, cell division cycle 20; CCNB2, cyclin B2; PTTG1, pituitary tumor-transforming 1; RFC4, replication factor C subunit 4; MCM2, minichromosome maintenance complex component 2.
27893964	0.90	securin, and Aurora A but not Ubch10.
20531406	0.89	AURKA, BUBR1, CCNB2, FANCI, MCM3, and PTTG1), whose mRNA levels decreased significantly after silencing of either TF (Supplementary Table V) confirmed that both TFs bind to their promoters (Figure 3E).
	0.84	AURKA, BUBR1, CCNB2, FANCI, MCM3, and PTTG1) and MRs (NFYB, E2F1, and E2F5) after MYB or FOXM1 silencing are indeed directly bound by them in their promoter region.
22535157	0.89	Aurora A CDC20, HMMR, NuSAP1, PLK1, PTTG1, TPX2, TTK, and UBE2C in ULMS (n = 8) compared with myometrium (n = 6) or leiomyoma (n = 6).
	0.72	PTTG1/securin, Aurora A/STK6, BUB1, BUB1B, CDC20, MAD2L1/MAD2, and Polo-like kinase 1 (PLK1; reviewed in ref.).
26445238	0.88	PTTG1 expression exhibited increased expression of cell proliferation-associated genes including CCNB1, CCNB2, CDK1, AURKA, BIRC5 and DEPDC1.
30911297	0.87	PTTG1 and AURKA expression levels for 71 MTC patients evaluated by qPCR.
	0.58	PTTG1 and AURKA (Aurora kinase A) expression.
16987420	0.86	Stk6 (Aurka), Nek2, Stathmin 1, Ckap2, Pttg1 (Securin), Cdc20, Mad2l1 (Table 1).
31423162	0.82	AURKA, BIRC5, BUB1B, CCNB1, CCNB2, CDC20, CDK1, CDKN3, CENPF, PRC1, PTTG1, TOP2A, TPX2, UBE2C and ZWINT) were present in MEblue.
21082037	0.81	PTTG1, ESPL1, TOP2A, NEK2, AURKA, TPX2, PLK1, etc.
31322260	0.79	AURKA, CCNB2, MAD2L1, HMMR, TTK, EZH2, CDC20, PTTG1, RACGAP1 and NCAPG (Table I).
22956538	0.78	Aurora A inhibitor did indeed maintain high levels of securin, unlike cells treated with RO-3306 alone (Fig. 2F), whilst ectopic expression of Emi1 could block premature disengagement in RO-3306 treated cells (Fig. 2C).
26894859	0.69	PTTG1, AURKA, AURKB, ECT2, PRC1, UBE2C, COX5A and COX10 and downregulation of LEPR and MN1
20436289	0.66	securin) and APCCdh1 (Aurora A, TPX2, Cdc20) substrates (Fig. 2E, Suppl.
20358275	0.62	AURKA, -B, MAPK4, SKP2, MYC, NPAT, POLS, PTTG1, RRM2, DLG7, INCENP, KCNH5, PPM1D, GINS4, H1F0, and KIFC1 are also not known with certainty, although some predictions are possible.